Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Paoletti

Showing results (41-50 of 145) with videos related to

Pageof 15
Sort By:
BMC Medical Research Methodology|February 26, 2013
Dealing with missing data in the Center for Epidemiologic Studies Depression self-report scale: a study based on the French E3N cohortNoémie Resseguier, Hélène Verdoux, Roch Giorgi, et al.
Psychological Medicine|April 5, 2007
Serious psychiatric outcome of subjects prenatally exposed to diethylstilboestrol in the E3N cohort studyHelene Verdoux, Jacques Ropers, Dominique Costagliola, et al.
The Lancet. Oncology|December 19, 2015
Precision medicine: lessons learned from the SHIVA trial - Authors' replyChristophe Le Tourneau, Lisa Belin, Xavier Paoletti, et al.
Biometrics|August 14, 2009
Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trialsNadine Houede, Peter F Thall, Hoang Nguyen, et al.
Plos One|December 20, 2012
Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agentsChristophe Le Tourneau, Hui K Gan, Albiruni R A Razak, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2013
A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trialsXavier Paoletti, Birgit Geoerger, François Doz, et al.
Journal of Clinical Microbiology|June 8, 2007
Shelf life of predosed plates containing mefloquine, artemisinin, dihydroartemisinin, and artesunate as used for in vitro Plasmodium falciparum susceptibility assessmentSandrine Houzé, Aline Munier, Xavier Paoletti, et al.
Urologic Oncology|October 6, 2014
Long-term follow-up of TaG1 non-muscle-invasive bladder cancerPierre Olivier Bosset, Yann Neuzillet, Xavier Paoletti, et al.
Eclinicalmedicine|November 8, 2021
Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysisCamille Moreau Bachelard, Elodie Coquan, Pauline du Rusquec, et al.
Discovery Medicine|November 2, 2010
Development of anti-cancer drugsJennifer Arrondeau, Hui K Gan, Albiruni R A Razak, et al.
Pageof 15

Showing results (41-50 of 145) with videos related to

Sort By:
Pageof 15
BMC Medical Research Methodology|February 26, 2013
Dealing with missing data in the Center for Epidemiologic Studies Depression self-report scale: a study based on the French E3N cohortNoémie Resseguier, Hélène Verdoux, Roch Giorgi, et al.
Psychological Medicine|April 5, 2007
Serious psychiatric outcome of subjects prenatally exposed to diethylstilboestrol in the E3N cohort studyHelene Verdoux, Jacques Ropers, Dominique Costagliola, et al.
The Lancet. Oncology|December 19, 2015
Precision medicine: lessons learned from the SHIVA trial - Authors' replyChristophe Le Tourneau, Lisa Belin, Xavier Paoletti, et al.
Biometrics|August 14, 2009
Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trialsNadine Houede, Peter F Thall, Hoang Nguyen, et al.
Plos One|December 20, 2012
Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agentsChristophe Le Tourneau, Hui K Gan, Albiruni R A Razak, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2013
A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trialsXavier Paoletti, Birgit Geoerger, François Doz, et al.
Journal of Clinical Microbiology|June 8, 2007
Shelf life of predosed plates containing mefloquine, artemisinin, dihydroartemisinin, and artesunate as used for in vitro Plasmodium falciparum susceptibility assessmentSandrine Houzé, Aline Munier, Xavier Paoletti, et al.
Urologic Oncology|October 6, 2014
Long-term follow-up of TaG1 non-muscle-invasive bladder cancerPierre Olivier Bosset, Yann Neuzillet, Xavier Paoletti, et al.
Eclinicalmedicine|November 8, 2021
Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysisCamille Moreau Bachelard, Elodie Coquan, Pauline du Rusquec, et al.
Discovery Medicine|November 2, 2010
Development of anti-cancer drugsJennifer Arrondeau, Hui K Gan, Albiruni R A Razak, et al.
Pageof 15